On October 15, 2025, Xuanzhu Biotech, a portfolio company of DNV Capital (DNVC), officially listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX). As its sole cornerstone investor, we take great pride in sharing this milestone moment with Xuanzhu.

As of today’s open, Xuanzhu Biotech surged strongly at HK29.46pershare—up153.9711.6—underscoring robust market confidence. Previously, the company’s public offering was 4,908.33 times oversubscribed, while its international placement received 10.15 times demand. In grey market trading, the stock already gained over 150%, translating to nearly HK$10,000 in paper profit per lot. This marks Xuanzhu as one of the most sought-after new biopharma stocks in Hong Kong’s healthcare sector this year.

DNV Capital has always believed that true investment value stems from hardcore innovation and industrial potential. As one of the few domestic biopharmaceutical companies with full-chain capabilities in both small-molecule and large-molecule drug development, Xuanzhu has built a pipeline of over 30 candidates over a decade—with more than 10 advancing into critical clinical stages or NDA submission.

As an innovation-driven biopharma firm, Xuanzhu has successfully developed a core portfolio of three approved products covering two key therapeutic areas: digestive system diseases and oncology. All three are Class I new drugs with core independent intellectual property rights, demonstrating its strong R&D and commercialization capabilities.

Among these:

​Anailazoprazole Sodium Enteric-coated Tablets (trade name: Anjiuwei®)​, China’s first self-developed proton pump inhibitor (PPI) for digestive diseases, was approved in 2023 for duodenal ulcers and quickly included in the national medical insurance catalog. By June 2025, it had achieved sales of RMB 48 million. Its unique metabolic pathway reduces the risk of drug-drug interactions, and it boasts superior clinical efficacy and safety compared to similar products. It is currently expanding indications to gastroesophageal reflux disease.

Pyrocinib Tablets (trade name: Xuan yuening®)​, a CDK4/6 inhibitor for oncology, was approved in 2025 for combination with fulvestrant to treat HR+/HER2- advanced breast cancer. Covering all treatment lines with excellent clinical data, it rapidly rolled out its first prescriptions post-launch and targets the domestic market, which is estimated to reach RMB 13 billion by 2032.

Deloakib Tablets (trade name: Xuanfeining®)​, a next-generation ALK inhibitor, was approved in August 2025 for ALK-positive advanced non-small cell lung cancer (NSCLC). With advantages including fast onset, strong tumor suppression, and the ability to cross the blood-brain barrier, it provides a new treatment option for drug-resistant patients and those with brain metastases—marking Xuanzhu’s expansion in oncology from breast cancer to lung cancer.

These three products form a strategic layout of “mature commercialization + potential new products”: the医保-included products stabilize cash flow, while newer assets target the multi-billion yuan oncology market. Together, they continue to address unmet clinical needs with high-quality treatment options.

Table: Gradient Analysis of Core Pipeline

DNV Capital manages over RMB 5 billion in assets and has been deeply engaged in the healthcare sector for years. It has led investments in dozens of well-known projects, including Haichuang Pharma, Pinci Medical, and Geneseeq Technology, and has won multiple industry awards. This deep partnership with Xuanzhu reflects not only our high recognition of its R&D strength but also another step forward in Delonix’s mission to support Chinese innovative drugs in going global.

Looking ahead, we will continue to empower Xuanzhu with capital and industrial resources, accompanying it in making breakthroughs in key therapeutic areas such as oncology and digestive diseases. Our goal is to bring more Chinese-origin innovative drugs to benefit patients worldwide.

About DNVc has invested in the project

About DNV Capital

DNV Capital unwaveringly adheres to the investent philosophy of "Focus, Specialization, Diversity, and Iintermationalization."'Thecompany has played a leading role in the investment of numerous renowned projects both domestically and intermationally, including but notlimited to venus Medtech (02500.HK), vessix Hypertension Treatment, Mitralign Artificial Heart Valve, Human Extension Surgical Robol(TASE:HUMX), Sorrento Biopharm(NASDAO: SRNE), Broncus Medical (02216.HK), Sonendo (NSE: SONX, Canbridge(01228.HK), Hinova Pharma (688302.SH), Geneseeg, Xuanzhu Biopharm, Binhui Biopharm, PINs Medical, Sinovation, and SurgeriTechnology.

In its future development, DNV Capital will remain tre to its founding principles, recall its mission, concentrate on excellence, andsteadfastly uphold a strategy rooted in intermationalization, diversification, and professionalism. Spanning major diseases such ascardiovascular conditions, cancer, and diabetes, as well as innovative medical devices and biopharmaceuticals in ophthalmology anddentistry, DNV Capital continuously supports innovation and extends services into various fields, including life sciences, cellular genetherapy, syuthetic biology, and artificial intelligence. The aim is to provide ongoing support in diverse areas and assist high-quality enterprisesand outstanding teams on their path to success.